Hongene Biotech is a producer of RNA building blocks – the first step for what’s possible in RNA drug-discovery and development. David Butler, Ph.D., Chief Technology Officer of Hongene, joins the Patient Empowerment Program to discuss why Hongene aims to help make RNA medicines accessible and affordable for patients everywhere, regardless of prevalence.

 

On this episode we discuss:

2:40 Hongene Biotech and what do they do

8:09 The early days of nucleoside building blocks and maturation of Hongene

12:00 Hongene is a strong supporter of n-Lorem. Why?

15:30 David’s origins in the chemistry field

17:38 Incremental progress that has been made in science and manufacturing

 

Links:

2024 Colloquium - https://www.nlorem.org/nano-rare-patient-colloquium-2024/

Make Hope Possible with a Donation - https://www.nlorem.org/donate/

Hongene - https://www.hongene.com/

 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör n-Lorem Foundation (Dr. Stan Crooke, Amy Williford, Kim Butler, Andrew Serrano, Jon Magnuson, and Kira Dineen). Innehållet i podden är skapat av n-Lorem Foundation (Dr. Stan Crooke, Amy Williford, Kim Butler, Andrew Serrano, Jon Magnuson, and Kira Dineen) och inte av, eller tillsammans med, Poddtoppen.